Sullivan Christopher Ryaninsider trades
In SEC Form 4 filings, Sullivan Christopher Ryan is listed as Chief Financial Officer of Avalo Therapeutics, Inc. (AVTX). In the last 90 days, Sullivan Christopher Ryan sold $381.9K of Avalo Therapeutics, Inc. (AVTX) on the open market and bought none. All 2 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | 6 | Sep 18 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-11
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| AVTXAvalo Therapeutics, Inc. | Sep 16 | Sep 18 | M | 12,394 | $9.88 | $122,453 | 52,294 | Yes | Form 4 |
| AVTXAvalo Therapeutics, Inc. | Sep 16 | Sep 18 | S | 12,394 | $16.33 | Sale −$202,437 | 39,900 | Yes | Form 4 |
| AVTXAvalo Therapeutics, Inc. | Sep 16 | Sep 18 | M · derivative | 12,394 | $9.88 | $122,453 | 83,848 | Yes | Form 4 |
| AVTXAvalo Therapeutics, Inc. | Sep 10 | Sep 11 | M | 10,185 | $8.04 | $81,887 | 50,085 | Yes | Form 4 |
| AVTXAvalo Therapeutics, Inc. | Sep 10 | Sep 11 | S | 10,185 | $17.62 | Sale −$179,457 | 39,900 | Yes | Form 4 |
| AVTXAvalo Therapeutics, Inc. | Sep 10 | Sep 11 | M · derivative | 10,185 | $8.04 | $81,887 | 105,815 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.